We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mobidiag and Unilabs Enter into Agreement
News

Mobidiag and Unilabs Enter into Agreement

Mobidiag and Unilabs Enter into Agreement
News

Mobidiag and Unilabs Enter into Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mobidiag and Unilabs Enter into Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mobidiag Ltd and Unilabs have announced an agreement covering the supply of Amplidiag products over the next four years for Unilabs in Sweden and Norway.

The Amplidiag product line covers six diagnostic products for various gastrointestinal infections, including tests for gastroenteritis, carbapenem- and vancomycin-resistance screening, as well as non-invasive Helicobacter pylori testing. The product line brings a major improvement to clinical laboratory processes, patient management and infection control measures by providing sensitive, comprehensive and rapid diagnostic results.

“Molecular diagnostics is gaining traction and becoming an increasingly important tool in improving patient diagnostics”, says Helena Enroth, PhD, responsible for R&D in molecular microbiology, Unilabs Sweden. “Implementing new multiplex molecular diagnostic tools is a step forward in our efforts to continuously improve our service portfolio and meet customer demands. Mobidiag is able to offer a comprehensive suite for gastrointestinal testing, and importantly, the products meet our expectations for large-scale use.”

“We are very happy to enter into this agreement”, says Tuomas Tenkanen, CEO of Mobidiag. “It is a major step forward in our efforts to enter the European market, and a major step in bringing Amplidiag products into the high-throughput use they have been designed for. This agreement solidifies our belief that we are able to create value together with our customers by bringing affordable molecular multiplex tests into clinical laboratory routines. We are very pleased to work together with Unilabs.”

Advertisement